

January 2019, Volume 80, Number 1

## CONTENTS

---

### Continuing Medical Education

- CME 1** Current controversies in early-stage melanoma  
Questions on incidence, screening, and histologic regression  
*Laura J. Gardner, MS, Jennifer L. Strunck, BS, Yelena P. Wu, PhD, and  
Douglas Grossman, MD, PhD*
- 13** **CME examination**
- 14** Answers to CME examination (Identification No. JA0119),  
January 2019 issue of the *Journal of the American Academy of  
Dermatology*
- CME 15** Current controversies in early-stage melanoma  
Questions on management and surveillance  
*Marki E. Klapperich, MD, Glen M. Bowen, MD, and  
Douglas Grossman, MD, PhD*
- 25** Answers to CME examination (Identification No. JB0119),  
January 2019 issue of the *Journal of the American Academy of  
Dermatology*
- 26** **CME examination**
- CME 27** Psoriasis: Which therapy for which patient  
Psoriasis comorbidities and preferred systemic agents  
*Shivani B. Kaushik, MD, and Mark G. Lebwohl, MD*
- 41** **CME examination**
- 42** Answers to CME examination (Identification No. JC0119),  
January 2019 issue of the *Journal of the American Academy of  
Dermatology*
- CME 43** Psoriasis: Which therapy for which patient  
Focus on special populations and chronic infections  
*Shivani B. Kaushik, MD, and Mark G. Lebwohl, MD*

---

Clinical cover image courtesy of Doug Grossman, MD, PhD. Histologic cover image courtesy of Scott Florell, MD.

Copyright © 2019 by the American Academy of Dermatology, Inc. *Journal of the American Academy of Dermatology* (ISSN: 0190-9622), is published monthly by Elsevier Inc., 230 Park Avenue, Suite 800, New York, NY 10169-0901, USA. Periodicals postage paid at New York, NY and additional mailing offices.

**POSTMASTER:** Send address changes to Elsevier, Journal Returns, 1799 Highway 50 East, Linn, MO 65051, USA.

	<b>53</b>	Answers to CME examination (Identification No. JD0119), January 2019 issue of the <i>Journal of the American Academy of Dermatology</i>
	<b>54</b>	<b>CME examination</b>
<b>Letter from the Editor</b>	<b>55</b>	Presentation of data <i>Dirk M. Elston, MD</i>
<b>A Clinician's Perspective</b>	<b>56</b>	"Tar smarts" may have a new meaning for atopic dermatitis and psoriasis <i>Warren R. Heymann, MD</i>
<b>From the Dermatology Foundation</b>	<b>58</b>	Use of a vibrating kinetic anesthesia device reduces the pain of lidocaine injections: A randomized split-body trial <i>William C. Fix, BA, Zelma C. Chiesa-Fuxench, MD, MSCE, Thuzar Shin, MD, PhD, Jeremy Eitzkorn, MD, Nicole Howe, MD, Christopher J. Miller, MD, and Joseph F. Sobanko, MD</i>
<b>Original Articles</b>	<b>60</b>	Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study <b>Bottom line: Adalimumab can be considered for long-term control of moderate-to-severe hidradenitis suppurativa.</b> <i>Christos C. Zouboulis, MD, PhD, Martin M. Okun, MD, Errol P. Prens, MD, PhD, Robert Gniadecki, MD, PhD, Peter A. Foley, MBBS, BMedSc, MD, FACD, Charles Lynde, MD, FRCPC, Jamie Weisman, MD, Yihua Gu, MS, David A. Williams, MD, MPH, and Gregor B. E. Jemec, MD, DMSc</i>
	<b>70</b>	Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study <b>Bottom line: Over 52 weeks, the overall safety of ixekizumab was comparable to that of ustekinumab.</b> <i>Carle Paul, MD, PhD, Christopher E. M. Griffiths, MD, Peter C. M. van de Kerkhof, MD, PhD, Lluís Puig, MD, PhD, Yves Dutronc, MD, Carsten Henneges, PhD, Martin Dossenbach, MD, Kristin Hollister, PhD, and Kristian Reich, MD, PhD</i>
	<b>80</b>	Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial <b>Bottom line: Apremilast is a promising new treatment modality for hidradenitis suppurativa; larger clinical studies are warranted.</b> <i>Allard R. J. V. Vossen, MD, Martijn B. A. van Doorn, MD, PhD, Hessel H. van der Zee, MD, PhD, and Errol P. Prens, MD, PhD</i>

- 89** A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis  
**Bottom line:** Tapinarof is a potential new treatment option for atopic dermatitis.  
*Johnny Peppers, PhD, Amy S. Paller, MD, Tomoko Maeda-Chubachi, MD, PhD, Sterling Wu, PhD, Kevin Robbins, BSc, LLM, Kelly Gallagher, MS, and John E. Kraus, MD, PhD*
- 99** Prognostic impact of regression in patients with primary cutaneous melanoma >1 mm in thickness  
**Bottom line:** Regression does not predict melanoma-specific survival in patients with melanomas >1 mm thick.  
*Simone Ribero, MD, PhD, Francesca Galli, MSC, Simona Osella-Abate, MSC, Luca Bertero, MD, Laura Cattaneo, MD, Barbara Merelli, MD, Carlo Tondini, MD, Laura Ghilardi, MD, Vincenzo De Giorgi, MD, Marcella Occelli, MD, Pietro Quaglino, MD, Paola Cassoni, MD, PhD, Giuseppe Palmieri, MD, PhD, Daniela Massi, MD, PhD, and Mario Mandala, MD, on behalf of the Italian Melanoma Intergroup*
- 106** Comparing the eighth and the seventh editions of the American Joint Committee on Cancer staging system and the Brigham and Women's Hospital alternative staging system for cutaneous squamous cell carcinoma: Implications for clinical practice  
**Bottom line:** The subgroup of tumors staged as T3 in the eighth edition of the American Joint Committee on Cancer staging system, which also showed a poor degree of differentiation, is a subgroup with greater risk.  
*Javier Cañueto, MD, PhD, Javier Burguillo, PhD, David Moyano-Bueno, MD, Alex Viñolas-Cuadros, MD, Alberto Conde-Ferreirós, MD, Luis Antonio Corchete-Sánchez, BS, MS, Jesús Pérez-Losada, MD, PhD, and Concepción Román-Curto, MD, PhD*
- 114** Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa  
**Bottom line:** Antiandrogen therapy with spironolactone may be a useful treatment option for reducing inflammatory lesions and pain for female patients with hidradenitis suppurativa.  
*Nicole M. Golbari, BA, Martina L. Porter, MD, and Alexa B. Kimball, MD, MPH*
- 120** Methotrexate for alopecia areata: A systematic review and meta-analysis  
**Bottom line:** Methotrexate is an effective monotherapy and adjunct to corticosteroids and should be considered in the treatment of severe AA in adults and children.  
*Kevin Phan, MD, Vignesh Ramachandran, BS, and Deshan Frank Sebaratnam, FACD*
- 128** Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials  
**Bottom line:** Glycopyrronium tosylate, now approved by the US FDA, is a noninvasive, once-daily, topical treatment option for primary axillary hyperhidrosis.  
*Dee Anna Glaser, MD, Adelaide A. Hebert, MD, Alexander Nast, MD, William P. Werschler, MD, Lawrence Green, MD, Richard Mamelok, MD, Janice Drew, MPH, John Quiring, PhD, and David M. Pariser, MD*

- 139** Sun protection behavior after diagnosis of high-risk primary melanoma and risk of a subsequent primary  
**Bottom line: Identifying patients with inadequate sun protection behaviors at diagnosis can assist clinicians in providing targeted education.**  
*Lena A. von Schuckmann, MBBS, MPH, Louise F. Wilson, MEpi, Maria Celia B. Hughes, MMedSci, Vanessa L. Beesley, PhD, Monika Janda, PhD, Jolieke C. van der Pols, PhD, B. Mark Smithers, MBBS, Kiarash Khosrotehrani, MD, PhD, and Adele C. Green, MBBS, PhD*
- 149** Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria  
**Bottom line: Identification of high-risk CM patients using 31-GEP testing supports its use to guide personalized clinical decisions.**  
*Brian R. Gastman, MD, Pedram Gerami, MD, Sarah J. Kurlay, PhD, Robert W. Cook, PhD, Sancy Leachman, MD, PhD, and John T. Vetto, MD*
- 158** Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis  
**Bottom line: Vaccination after 12-week dupilumab therapy was not associated with adverse clinical effects.**  
*Andrew Blauvelt, MD, MBA, Eric L. Simpson, MD, MCR, Stephen K. Tyring, MD, PhD, Lisa A. Purcell, PhD, Brad Shumel, MD, Christopher D. Petro, PhD, Bolanle Akinlade, MD, Abhijit Gadkari, PhD, Laurent Eckert, PhD, Neil M. H. Graham, MBBS, MD, MPH, Gianluca Pirozzi, MD, PhD, and Robert Evans, PharmD*
- 168** A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies  
**Bottom line: Once-daily, FMX101 topical minocycline foam 4% appears to be safe, well-tolerated, and effective in treating moderate-to-severe acne; minocycline foam represents an important treatment option for patients with acne.**  
*Linda Stein Gold, MD, Sunil Dhawan, MD, Jonathan Weiss, MD, Zoe Diana Draelos, MD, Herman Ellman, MD, and Iain A. Stuart, PhD*
- 

**Dermatologic  
Surgery**

- 178** Clinical spectrum of cutaneous melanoma morphology  
**Bottom line: Awareness of the diversity of melanoma appearances and their associated clinical factors might help dermatologists improve their diagnostic accuracy.**  
*Nikolai Klebanov, BS, Nicole S. Gunasekera, MD, MBA, William M. Lin, MD, Elena B. Hawryluk, MD, PhD, David M. Miller, MD, PhD, Bobby Y. Reddy, MD, Mitalee P. Christman, MD, Derek Beaulieu, MD, Suvithan Rajadurai, BS, Lyn M. Duncan, MD, Arthur J. Sober, MD, and Hensin Tsao, MD, PhD*

**Dermatopathology** 189

Appropriate use criteria in dermatopathology: Initial recommendations from the American Society of Dermatopathology

**Bottom line: Appropriate use criteria can affect health care delivery, inform reimbursement policy, and guide physician decision making.**

*Task Force/Committee Members: Claudia I. Vidal, MD, PhD, Eric A. Armbract, PhD, Aleodor A. Andea, MD, Angela K. Bohlke, MD, PhD, Nneka I. Comfere, MD, Sarah R. Hughes, MD, Jinah Kim, MD, PhD, Jessica A. Kozel, MD, Jason B. Lee, MD, Konstantinos Linos, MD, Brandon R. Litzner, MD, Tricia A. Missall, MD, PhD, Roberto A. Novoa, MD, Uma Sundram, MD, PhD, Brian L. Swick, MD, M. Yadira Hurley, MD (Chair)*  
*Rating Panel: Murad Alam, MD, MSCI, MBA, Zsolt Argenyi, MD, Lyn M. Duncan, MD, Dirk M. Elston, MD, Patrick O. Emanuel, MBChB, Tammie Ferringer, MD, Maxwell A. Fung, MD, Gregory A. Hosler, MD, PhD, Alexander J. Lazar, MD, PhD, Lori Lowe, MD, Jose A. Plaza, MD, Victor G. Prieto, MD, PhD, June K. Robinson, MD, Andras Schaffer, MD, PhD, Antonio Subtil, MD, MBA, and Wei-Lien Wang, MD*

**From the Academy** 208

Guidelines of care for the management of primary cutaneous melanoma

*Work Group: Susan M. Swetter, MD (Chair), Hensin Tsao, MD, PhD (Co-Chair), Christopher K. Bichakjian, MD, Clara Curiel-Lewandrowski, MD, David E. Elder, MBChB, Jeffrey E. Gershenwald, MD, Valerie Guild, MS, MBA, Jane M. Grant-Kels, MD, Allan C. Halpern, MD, Timothy M. Johnson, MD, Arthur J. Sober, MD, John A. Thompson, MD, Oliver J. Wisco, DO, Samantha Wyatt, MD, Shasa Hu, MD, and Toyin Lamina, PhD*

**Reviews** 251

Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies

**Bottom line: Screening patients with psoriasis for psoriatic arthritis may be warranted, especially for those with moderate-to-severe disease.**

*Farzad Alinaghi, MD, Monika Calov, MD, Lars Erik Kristensen, MD, PhD, Dafna D. Gladman, MD, FRCPC, Laura C. Coates, MBChB, MRCP, PhD, Denis Jullien, MD, PhD, Alice B. Gottlieb, MD, PhD, Paolo Gisondi, MD, Jashin J. Wu, MD, Jacob P. Thyssen, MD, PhD, DMSc, and Alexander Egeberg, MD, PhD*

266

Review of environmental effects of oxybenzone and other sunscreen active ingredients

**Bottom line: Health care providers should encourage photoprotection including shade, photoprotective clothing, and applying appropriate sunscreens on exposed skin.**

*Samantha L. Schneider, MD, and Henry W. Lim, MD*

**Research Letters** 272

Survival of patients with early invasive melanoma down-staged under the new eighth edition of the American Joint Committee on Cancer staging system

*Lena A. von Schuckmann, MBBS, MPH, Maria Celia B. Hughes, MMedSci, Rebecca Lee, MBChB, Paul Lorigan, MB, FRCP, Kiarash Khosrotehrani, MD, PhD, B. Mark Smithers, MBBS, and Adele C. Green, MBBS, PhD*

	<b>274</b>	Pharmacy costs of specialty medications for plaque psoriasis in the United States <i>Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, and Tina Bhutani, MD</i>
	<b>275</b>	Analysis of national skin cancer expenditures in the United States Medicare population, 2013 <i>Emily Stamell Ruiz, MD, MPH, Frederick C. Morgan, BSPH, Corwin M. Zigler, PhD, Robert J. Besaw, MPH, and Chrysalyn D. Schmults, MD, MSCE</i>
	<b>278</b>	Survey analysis on the management of moderately dysplastic nevi among academic dermatologists across the United States <i>Kristen M. Tessitore, MS, BS, Hyunji Choi, MD, Ambuj Kumar, MD, MPH, and Nishit S. Patel, MD</i>
	<b>280</b>	Dupilumab use in allergic contact dermatitis <i>Brian C. Machler, MD, Calvin T. Sung, BS, Evan Darwin, BS, and Sharon E. Jacob, MD</i>
	<b>281</b>	Growth in the cost of biologics in Medicare beneficiaries, 2013 to 2016 <i>Partik Singh, BA, and Jonathan I. Silverberg, MD, MPH, PhD</i>
	<b>282</b>	Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis <i>Mark G. Lebwohl, MD, Jeffrey L. Sugarman, MD, PhD, Linda Stein Gold, MD, David M. Pariser, MD, Tina Lin, PharmD, Radhakrishnan Pillai, PhD, Gina Martin, MOT, Susan Harris, MS, and Robert Israel, MD</i>
	<b>285</b>	Assessment of clinician accuracy for diagnosing melanoma on the basis of electrical impedance spectroscopy score plus morphology versus lesion morphology alone <i>Ryan M. Svoboda, MD, MS, Giselle Prado, MD, Rachel S. Mirsky, BA, and Darrell S. Rigel, MD, MS</i>
<b>Dermatoethics Consultation</b>	<b>288</b>	Parental decisions for adolescent patients: Ethical considerations of information withholding <i>Jonathan M. Soh, MD, Mary Gail Mercurio, MD, and Lisa A. Beck, MD</i>
<b>Dermatology Grand Rounds at the NIH</b>	<b>291</b>	Recurrent fevers, progressive lipodystrophy, and annular plaques in a child <i>Michael A. Cardis, MD, Gina A. Montealegre Sanchez, MD, MS, Raphaela Goldbach-Mansky, MD, MHSc, Chyi-Chia Richard Lee, MD, PhD, and Edward W. Cowen, MD, MHSc</i>
<b>Beyond JAAD</b>	<b>296</b>	Beyond JAAD January 2019: Articles of interest to dermatologists from the nondermatologic literature <i>Andrew Bronin, MD, Robert Phelps, MD, and Robert Sidbury, MD</i>

<b>Correction</b>	<b>301</b>	Blauvelt A, Gooderham M, Iversen L, et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). <i>J Am Acad Dermatol.</i> 2017;77:855-862
-------------------	------------	---

**JAAD ONLINE**

**Available at <http://www.jaad.org>**

<b>Clinical Pearl</b>	<b>e1</b>	Using a car phone holder for performing oculoscopy with a universal serial bus dermatoscope <i>Deepak Jakhar, MD, and Chander Grover, MD, DNB, MNAMS</i>
<b>Therapeutic Pearl</b>	<b>e3</b>	Lightening Becker nevus with topical glycolic acid <i>Yiping Zhong, MD, Yongjun Chen, MD, Lining Huang, MD, Hui Wang, MD, Tingting Yan, MD, Bin Yang, MD, and Mao-Qiang Man, MD</i>
<b>Surgical Pearl</b>	<b>e5</b>	Video chat to prevent wrong site surgery <i>Ramona Behshad, MD, and Joseph Muccini, MD</i>
<b>Technology Pearl</b>	<b>e7</b>	Reflectance confocal microscopy as a novel tool for presurgical identification of basal cell carcinoma biopsy site <i>Cristián Navarrete-Dechent, MD, Shoko Mori, BS, Miguel Cordova, MD, and Kishwer S. Nehal, MD</i>
<b>Notes &amp; Comments</b>	<b>e9</b>	Kalava-induced foreign body reaction <i>Rachita Misri, MD, Deepak Jakhar, MD, Rakesh Gupta, MD, and Smriti Kumar, MBBS</i>
	<b>e11</b>	Reply to: "Kalava-induced foreign body reaction" <i>Mayra B. C. Maymone, MD, DSc, Roopal V. Kundu, MD, and Neelam A. Vashi, MD</i>
	<b>e13</b>	Aspirin use and the risk of malignant melanoma <i>Lenard M. Lichtenberger, PhD, and Shelley Burge, MEd</i>
	<b>e15</b>	Reply to: "Aspirin use and the risk of malignant melanoma" <i>Kelsey A. Orrell, MB BCh BAO, Alfred W. Rademaker, PhD, Dennis P. West, PhD, and Beatrice Nardone, MD, PhD</i>
	<b>e17</b>	Use of immortal time within survival analysis <i>Linda Chan, MBBS, Karen Byth, PhD, and Pablo Fernandez-Penas, MD, PhD</i>
	<b>e19</b>	Reply to: "Use of immortal time within survival analysis" <i>Charles Kyung Min Lee, BS, Shufeng Li, MS, Duy Cong Tran, BS, Gefei Alex Zhu, MD, Jinah Kim, MD, PhD, Bernice Y. Kwong, MD, and Anne Lynn S. Chang, MD</i>
	<b>e21</b>	Comment on "Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma" <i>Serigne N. Lo, PhD, Matthew Stodell, MD, Richard A. Scolyer, MD, and John E. Thompson, MD</i>

**Contents** *continued*

	<b>e23</b>	Comment on: “The first 30 years of the American Academy of Dermatology skin cancer screening program: 1985-2014” <i>Dayoung Ko, BS, and Shari R. Lipner, MD, PhD</i>
<b>Book Review</b>	<b>e25</b>	Dermatologic surgery <i>Michelle Xu, MD</i>
<b>Iotaderma</b>	<b>e27</b>	Iotaderma #299 <i>Robert I. Rudolph, MD, FACP</i>

To access the current version of the Information for Authors, Transfer of Copyright Form, Authorship Declaration Form, Conflict of Interest Disclosure, and Authors’ Rights Statement, as well as many other pertinent documents, please visit our website at [www.jaad.org/content/auth\\_page](http://www.jaad.org/content/auth_page).

Full text access to *Journal of the American Academy of Dermatology Online* is now available for Academy members and all print subscribers. To activate your online subscription, please visit *Journal of the American Academy of Dermatology Online* by pointing your browser to <http://www.jaad.org>.

**Icon Key**

	=	<b>CME article</b>
	=	<b>Video content available at <a href="http://www.jaad.org">http://www.jaad.org</a></b>
	=	<b>Podcast available at <a href="http://www.aad.org/olc">http://www.aad.org/olc</a></b>
	=	<b>MOC credits available</b>

**Early online publication: Articles in press**

The *Journal of the American Academy of Dermatology* posts in-press articles online before they appear in the print edition of the *Journal*. These Articles in Press are available from both the JAAD website ([www.jaad.org](http://www.jaad.org)) and Science Direct ([www.sciencedirect.com](http://www.sciencedirect.com)). To access Articles in Press, simply click the Articles in Press link.

**JAAD Case Reports**

The *Journal of the American Academy of Dermatology* no longer publishes Case Reports. These can now be found in our new open access journal, *JAAD Case Reports*, at <http://www.jaadcasereports.org>.